View More Recent Stories

Feb 23, 2017 07:46AM Trevena (TRVN) PT Lowered to $8 at H.C. Wainwright on Disappointing Phase 3 APOLLO Results
Feb 22, 2017 07:21AM Cidara Therapeutics (CDTX) PT Lowered to $18 at H.C. Wainwright Following Phase 2 Radiant Study Results
Feb 15, 2017 07:17AM H.C. Wainwright Downgrades Aviragen Therapeutics (AVIR) to Neutral
Feb 7, 2017 07:33AM Aurinia Pharmaceuticals (AUPH): First Take On CEO Transition - HC Wainwright
Feb 3, 2017 09:59AM FOURIER Data Good For Amgen (AMGN), Better for The Medicines Company (MDCO) - H.C. Wainwright
Jan 31, 2017 08:08AM Ocera Therapeutics (OCRX): Cutting PT to $4 - HC Wainwright
Jan 30, 2017 07:05AM H.C. Wainwright Upgrades CymaBay Therapeutic (CBAY) to Buy
Jan 9, 2017 07:04AM H.C. Wainwright Starts Trevena (TRVN) at Buy
Jan 4, 2017 07:24AM CymaBay Therapeutics (CBAY): Raising PT After Deal Announcement - H.C. Wainwright
Dec 30, 2016 07:04AM Aurinia Pharmaceuticals (AUPH) PT Trimmed to $8 at H.C. Wainwright on Dilution; 'Buy' Maintained
Dec 28, 2016 07:04AM H.C. Wainwright Starts Ocera Therapeutics (OCRX) at Buy, $10 PT
Dec 27, 2016 07:30AM Akebia Therapeutics (AKBA): Phase III Funding In The Bag - HC Wainwright; PT up to $18
Dec 20, 2016 07:28AM Conatus Pharmaceuticals (CNAT) PT Raised to $18 at H.C. Wainwright on Novartis Deal
Dec 19, 2016 07:14AM H.C. Wainwright Starts Cidara Therapeutics (CDTX) at Buy
Dec 5, 2016 08:20AM AcelRx (ACRX) ARX-04 Well-Positioned for Approval - H.C. Wainwright
Nov 29, 2016 07:15AM Recro Pharma (REPH): Second Meloxicam Phase 3 Trial Achieves Positive Results - REPH
Nov 14, 2016 07:22AM Recro Pharma (REPH): Phase 3 Data, A Catalyst This Quarter - HC Wainwright
Nov 7, 2016 07:52AM Aurinia Pharmaceuticals (AUPH): EOP2 Meeting Results Were Better Than Could Have Been Hoped For - HC Wainwright
Oct 5, 2016 07:49AM Aurinia Pharmaceuticals (AUPH): Reiterating $10 PT After The Recent 33% Move - HC Wainwright
Sep 29, 2016 07:06AM H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral
Sep 21, 2016 10:53AM Galectin Therapeutics (GALT) Gains Again on Takeover, NASH Trial Speculation
Sep 20, 2016 01:09PM Galectin Therapeutics (GALT) May Have Best Read-Through From Allergan's Tobira (TBRA) Deal - H.C. Wainwright's Arce
View More Recent Stories